Tumor Biology

, Volume 37, Issue 1, pp 437–446 | Cite as

Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer

  • David L. Kolin
  • Keiyan Sy
  • Fabio Rotondo
  • Mena N. Bassily
  • Kalman Kovacs
  • Christine Brezden-Masley
  • Catherine J. Streutker
  • George M. Yousef
Original Article

Abstract

Human tissue kallikrein-related peptidases (KLK) are a group of 15 serine proteases which have been investigated as potential cancer biomarkers. This study determined the prognostic significance of KLK 11 and 15 expression levels in gastric carcinoma specimens. Expression of KLK11 and KLK15 was assessed by immunohistochemistry staining on a tissue microarray constructed from 113 gastrectomy specimens from patients with gastric carcinoma. To minimize inter-observer variability, expression levels were quantified using an automated algorithm. Epithelial and stromal staining were assessed separately. Both KLK11 and KLK15 were expressed in gastric carcinoma. There was no significant correlation between either KLK11 or KLK15 expression and the presence of lymph node metastases or Lauren classification (intestinal vs. diffuse). Higher levels of KLK11 expression in gastric carcinoma were associated with significantly worse overall survival (p = 0.008), and a multivariate analysis showed that it had prognostic value independent of tumor stage and differentiation (p = 0.004). Variations in KLK15 expression were not significantly associated with prognosis. KLK11 shows promise as a potential independent prognostic marker for gastric carcinoma.

Keywords

Gastric cancer Kallikreins KLK11 KLK15 Tumor markers Personalized medicine 

Notes

Acknowledgments

This work was supported by grants from the Kidney Foundation of Canada, the Kidney Cancer Research Network of Canada, Prostate Cancer Canada, and the Canadian Institute of Health Research.

Conflict of interest

None.

References

  1. 1.
    Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.CrossRefPubMedGoogle Scholar
  2. 2.
    Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto; 2014.Google Scholar
  4. 4.
    Shah MA, Ajani JA. Gastric cancer—an enigmatic and heterogeneous disease. JAMA. 2010;303:1753–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22:184–204.PubMedGoogle Scholar
  7. 7.
    Shaw JLV, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53:1423–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem. 2001;276:53–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4:876–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Yousef GM, Obiezu CV, Luo L-Y, Magklara A, Borgoño CA, Kishi T, et al. Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem. 2005;39:11–79.CrossRefPubMedGoogle Scholar
  11. 11.
    Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med. 2012;50:1877–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 2008;54:1600–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Kontos CK, Mavridis K, Talieri M, Scorilas A. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: mechanistic and clinical aspects. Thromb Haemost. 2013;109:450–7.CrossRefGoogle Scholar
  14. 14.
    Patsis C, Yiotakis I, Scorilas A. Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. Clin Biochem. 2012;45:623–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol. 2003;21:3119–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer. 2002;87:1294–300.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Nakamura T, Stephan C, Scorilas A, Yousef GM, Jung K, Diamandis EP. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology. 2003;61:1042–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Bi X, He H, Ye Y, Dai Q, Han Z, Liang Y, et al. Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer. Med Oncol. 2010;27:145–51.CrossRefPubMedGoogle Scholar
  19. 19.
    Stavropoulou P, Gregorakis AK, Plebani M, Scorilas A. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta. 2005;357:190–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Rabien A, Fritzsche FR, Jung M, Tölle A, Diamandis EP, Miller K, et al. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. Int J Cancer. 2010;127:2386–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Mavridis K, Stravodimos K, Scorilas A. Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression. Prostate. 2013;73:1191–201.CrossRefPubMedGoogle Scholar
  22. 22.
    Wen Y-G, Wang Q, Zhou C-Z, Yan D-W, Qiu G-Q, Yang C, et al. Identification and validation of Kallikrein-ralated peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry. J Surg Oncol. 2011;104:516–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Lei K-F, Liu B-Y, Zhang X-Q, Jin X-L, Guo Y, Ye M, et al. Development of a survival prediction model for gastric cancer using serine proteases and their inhibitors. Exp Ther Med. 2012;3:109–16.CrossRefPubMedGoogle Scholar
  24. 24.
    Kolin DL, Sy K, Rotondo F, Bassily MN, Kovacs K, Brezden-Masley C, et al. Prognostic significance of human tissue kallikrein-related peptidases 6 and 10 in gastric cancer. Biol Chem. 2014;395:1087–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 1996;56:3371–9.PubMedGoogle Scholar
  26. 26.
    Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291–9.PubMedGoogle Scholar
  27. 27.
    Linder N, Konsti J, Turkki R, Rahtu E, Lundin M, Nordling S, et al. Identification of tumor epithelium and stroma in tissue microarrays using texture analysis. Diagn Pathol. 2012;7:22.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Fadem B. High-yield behavioral science (high-yield series). Hagerstwon: Lippincott Williams & Wilkins; 2008.Google Scholar
  29. 29.
    Van Belle G. Statistical rules of thumb. 2nd ed. Hoboken: Wiley; 2008.CrossRefGoogle Scholar
  30. 30.
    Freedman DA. Statistical models: theory and practice. Cambridge: Cambridge University Press; 2005.CrossRefGoogle Scholar
  31. 31.
    Feng B, Xu W-B, Zheng M-H, Ma J-J, Cai Q, Zhang Y, et al. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol. 2006;21:1596–603.CrossRefPubMedGoogle Scholar
  32. 32.
    Liu X, Xiong H, Li J, He Y, Yuan X. Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer. Diagn Pathol. 2013;8:62.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Kim JJ, Kim J-T, Yoon HR, Kang MA, Kim JH, Lee Y-H, et al. Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer. Tumour Biol. 2012;33:731–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Scorilas A, Mavridis K. Kallikrein-related peptidases (KLKs) as novel potential biomarkers in gastric cancer: an open yet challenging road lies ahead. J Surg Oncol. 2012;105:223–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Sawant S, Snyman C, Bhoola K. Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. Int Immunopharmacol. 2001;1:2063–80.CrossRefPubMedGoogle Scholar
  36. 36.
    Yousef GM, Borgoño CA, White NM, Robb J-D, Michael IP, Oikonomopoulou K, et al. In silico analysis of the human kallikrein gene 6. Tumour Biol. 2004;25:282–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, et al. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res. 2005;11:6800–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Zhao E-H, Shen Z-Y, Liu H, Jin X, Cao H. Clinical significance of human kallikrein 12 gene expression in gastric cancer. World J Gastroenterol. 2012;18:6597–604.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem. 2010;43:1205–11.CrossRefPubMedGoogle Scholar
  40. 40.
    Huang W, Zhong J, Wu L-Y, Yu L-F, Tian X-L, Zhang Y-F, et al. Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett. 2007;251:78–85.CrossRefPubMedGoogle Scholar
  41. 41.
    Unal D, Tasdemir A, Oguz A, Eroglu C, Cihan YB, Turak EE, et al. Is human kallikrein-11 in gastric cancer treated with surgery and adjuvant chemoradiotherapy associated with survival? Pathol Res Pract. 2013;209:779–83.CrossRefPubMedGoogle Scholar
  42. 42.
    Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One. 2012;7:e37379.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Sano A, Sangai T, Maeda H, Nakamura M, Hasebe T, Ochiai A. Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int J Oncol. 2007;30:1493–8.PubMedGoogle Scholar
  44. 44.
    Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • David L. Kolin
    • 1
    • 2
  • Keiyan Sy
    • 3
  • Fabio Rotondo
    • 1
  • Mena N. Bassily
    • 4
  • Kalman Kovacs
    • 1
  • Christine Brezden-Masley
    • 5
  • Catherine J. Streutker
    • 1
    • 2
  • George M. Yousef
    • 1
    • 2
    • 6
  1. 1.Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science of St. Michael’s HospitalTorontoCanada
  2. 2.Department of Laboratory Medicine and PathobiologyUniversity of TorontoTorontoCanada
  3. 3.Department of PathologyCredit Valley HospitalMississaugaCanada
  4. 4.Department of Community Medicine and Public HealthMenoufiya UniversityShebeen el komEgypt
  5. 5.Department of Medicine and Hematology-OncologySt. Michael’s HospitalTorontoCanada
  6. 6.Department of Laboratory MedicineSt. Michael’s HospitalTorontoCanada

Personalised recommendations